Our Mission Statement:

“TransCelerate BioPharma will develop shared industry research and development solutions to simplify and accelerate the delivery of innovative products to patients.  Our non-profit, procompetitive model will be based on a results-oriented approach, emphasizing increased quality in clinical studies and improved patient safety, enabled by broad participation and collaboration across the global research and development community.”

 

The launch of TransCelerate BioPharma – with the support of ten major biopharmaceutical companies – has been enthusiastically welcomed by the wider drug development community. This is not the first time that the biopharmaceutical industry has collaborated to solve common challenges, but it is one of the most ambitious and supported collaborations to date. The mission of TransCelerate has garnered significant support from the biopharmaceutical industry at large, as well as regulators, other clinical trial collaborations and the general clinical trial ecosystem.

 

In just six months, we have made significant strides toward our initial aim of making selected components of clinical trials more efficient. The five ongoing initiatives are making strong progress towards their goals, and in the future, we will launch other initiatives also aimed at the pre-competitive drug development environment. My colleagues from the member companies of TransCelerate and I have an unwavering commitment to assessing, refining and creating processes to bring innovative new medicines to the public faster. I urge you to frequent this site for important updates on our initiatives and milestones.

 

Sincerely,

 

Dalvir Gill, Ph.D.

Chief Executive Officer

TransCelerate BioPharma Inc.

 

Please find more information about Dr. Gill on our Governance page.

 

---

About Us

 

In September 2012, ten leading pharmaceutical companies formed the non-profit organization TransCelerate BioPharma Inc. (TransCelerate), with a focus on accelerating the development of new medicines – initially by identifying ways to make the clinical trial process more efficient.

 

TransCelerate seeks to advance innovation in research and development (R&D), identify and solve common R&D challenges and further improve patient safety, with the goal of delivering more high quality medicines to patients. TransCelerate will seek to accomplish these objectives through its focus on identifying and capturing efficiencies in the clinical trial process, which will reduce costs, increase speed to market, and enhance quality, innovation and patient safety.

 

After an extensive evaluation process, TransCelerate has taken steps to advance five collaboration projects:

• Standardized Approach for High-Quality, Risk-Based Monitoring
• Shared Site Qualification and Training
• Common Investigator Site Portal
• Clinical Data Standards – Efficacy
• Comparator Drugs for Clinical Trials

 

For more information on the five initial projects, please visit our Initiatives page.

 

TransCelerate evolved from discussions at various forums for executive R&D leadership to discuss relevant issues facing the industry and solutions for addressing common challenges. TransCelerate filed for incorporation on August 15, 2012. Executive offices are located in Philadelphia, PA.

 

Membership in TransCelerate is open to all pharmaceutical and biotechnology companies who can contribute to and benefit from these shared solutions. For more information, please visit our Membership page.

• TransCelerate announces methodology for risk-based monitoring of clinical trials on June 3, 2013. Please click here to read more.
• TransCelerate announces six new members on April 15, 2013. Please click here to read more.